Insider · CIK 0001658390
Alexandra Glucksmann
Files at RGNX (REGENXBIO Inc.). First filing -, latest -.
Alexandra Glucksmann files SEC Form 4 as director at RGNX (REGENXBIO Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Alexandra Glucksmann has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +7,768 | $0.00 | $0 | 19,054 | Jun 3, 2025 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +39,815 | $0.00 | $0 | 39,815 | Jun 3, 2025 |
Questions about Alexandra Glucksmann
Answered from the filings on this page, as of the latest one.
Is Alexandra Glucksmann buying or selling?
Alexandra Glucksmann has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Alexandra Glucksmann's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Alexandra Glucksmann has 0.
Where does Alexandra Glucksmann file Form 4?
Alexandra Glucksmann has filed Form 4 at RGNX (REGENXBIO Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.